. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2011 Jul 23;9(10):902–909.e1. doi: 10.1016/j.cgh.2011.07.006

Table 3.

Effect of baseline MDB, MDB gain, and MDB loss on clinical and histological outcomes

Outcome	Unadjusted			Adjusted^‡
Outcome	Ratio^†	95% Cl	P value	Ratio^†	95% Cl	P value
*MDBs Present on Baseline Biopsy*
Clinical	1.62	1.21–2.15	0.001	0.96	0.71–1.30	0.79
Histological	2.80	1.57–5.01	<0.001	1.97	1.03–3.80	0.04
*MDB Gain*
Clinical	3.93	2.58–5.97	<0.001	2.81	1.83–4.32	<0.001
Histological	5.18	2.15–12.48	<0.001	4.02	1.57–10.28	0.004
*MDB Loss*
Clinical	0.73	0.31–1.76	0.49	1.09	0.42–2.90	0.85
Histological	0.79	0.12–5.15	0.80	0.41	0.05–3.76	0.43

^†

Hazard Ratio for Clinical and non-HCC clinical outcome; Odds Ratio for Histological outcome

^‡

Adjusted for baseline albumin, platelet, AST/ALT ratio, fibrosis, steatosis, and interaction between fibrosis and steatosis.